Abstract
The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Current Psychopharmacology
Title: Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Volume: 1
Author(s): Xiuping Chen, Jiajie Guo, Jiaolin Bao, Wenshan Xu, Yanjuan Huang and Yitao Wang
Affiliation:
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Abstract: The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Export Options
About this article
Cite this article as:
Chen Xiuping, Guo Jiajie, Bao Jiaolin, Xu Wenshan, Huang Yanjuan and Wang Yitao, Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010103
DOI https://dx.doi.org/10.2174/2211556011201010103 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) In Vivo Inhibition of the Estrogen Sulfatase Enzyme and Growth of DMBA-Induced Mammary Tumors by Melatonin
Current Cancer Drug Targets Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters Identification of Tumor Targeting Agents by Phage Display
Medicinal Chemistry Reviews - Online (Discontinued) Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals “Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design